eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank



 
4/2012
vol. 50
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy of the first and subsequent courses of anti-TNF therapy in patients with ankylosing spondylitis – results from the Czech National Register ATTRA

Karel Pavelka, Markéta Fojtíková, Karel Hejduk

Reumatologia 2012; 50, 4: 294–306
Online publish date: 2012/09/07
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Background: Efficacy of switching of anti-tumour necrosis factor (anti-TNF) in ankylosing spondylitis (AS) in real clinical practice is not fully known.

Objective: The aim of the study was to compare efficacy of the first and the second course of anti-TNF in patients with AS using data from ATTRA.

Material and methods: Patients fulfilled criteria of CRS for indication of anti-TNF. Outcomes used: BASDAI, C-reactive protein (CRP) (mg/l), enthesitis index and survival on drug during 1 year.

Results: In total 1175 patients were included, of whom 1012 had received the first course of anti-TNF only (“non-switchers”), and 163 the second anti-TNF course (“switchers”). Survival during 1–4 years in “non-switchers” was 91%, 86%, 81% and 78% and in switchers 81%, 69%, 60%, 48%. Decrease of CRP was greater in the non-switcher group than in the switcher group in all measured intervals. However, there was not a different proportion of patients who reached BASDAI < 4 in both groups.

Conclusions: This study shows that the second anti-TNF therapy in AS is only a little bit less effective than the 1st anti-TNF and that switching of therapy is reasonable. 80% and 70% of the patients remain on the second anti-TNF after 1 and 2 years, approximately half of the patients reach major clinical response and the same proportion of patients reach low activity corresponding to a partial remission.
keywords:

ankylosing spondylitis, anti-TNF therapy

references:
Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 (Suppl. 3): iii8-iii18.
Zochling J, van der Heijde D, Burgos-Vargas R, et al.; “ASsessment in AS” international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-452.
Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondylarthritis. Ann Rheum Dis 2011; 70: 905-908.
Braun J, Landewé R, Hermann KG, et al.; ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54: 1646-1652.
Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63: 1543-1551.
van der Heijde D, Kivitz A, Schiff HM, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-2146.
Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-3412.
Cantini F, Nicooli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006; 55: 812-816.
Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011; 70: 157-163.
Conti F, Ceccareli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007; 66: 1393-1397.
Paccou J, Solau-Gervais E, Houvenagel E, et al. Efficacy in current practice of switching between anti-tumour necrosis factor-  agents in spondyloarthropathies. Rheumatology (Oxford) 2011; 50: 714-20.
Pavelka K. Long-term efficacy and safety of anti-TNF therapies in ankylosing spondylitis, experiences from nation-wide registry ATTRA. Hungarian Rheumatology 2010; 51: 154 (O11).
Pavelka K. Guidelines of the Czech Rheumatological Society for treatment of ankylosing spondylitis in Czech. Česká Revmatol 2012; 1: 4-11.
Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36: 801-808.
Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011; 70: 157-163.
Hyrich KL, Lunt M, Dixon WG, et al. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008; 47: 1000-1005.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe